Don't Let Sponsors Downplay Genuine Safety Concerns At Public Hearings, HAI Tells EMA
This article was originally published in SRA
Executive Summary
After the European Medicines Agency's pharmacovigilance committee (PRAC) finalized rules on how it would conduct public hearings to support the safety review of certain marketed medicines earlier this month1-3, medicines advocacy group Health Action International said that it welcomed the move, but warned that drug sponsors should not be allowed to downplay genuine safety concerns at such hearings.
You may also be interested in...
Waiting For The Perfect Case: Why EMA Has Yet To Hold A Public Drug Safety Hearing
The European Medicines Agency has yet to use the power it has to hold public hearings on marketed medicines that raise safety concerns. It says it will do so only when the time is right.
EMA Public Hearings On Marketed Medicines To Start Next Year
The European Medicines Agency is set to give EU citizens a voice in the safety evaluation of marketed medicines by holding its first public hearing next year, though no specific topic or date has been decided.
EU Drug Safety Actions Speeded Up By New Legislation, Says Commission
The European Commission reports that new regulatory tools made available under the revised pharmacovigilance legislation have allowed drug safety issues to be detected and acted upon more rapidly, and that further improvements to the system are in the pipeline.